Celltrion/Teva Rituxan biosimilar edges closer to US approval
Experts call for lower disease activity threshold for biologic drugs
Drugmaker could file in EU in coming weeks, according to report
Regulator cites issues with manufacturing plant
Mundipharma’s third biosimilar tie-up with Celltrion
Phase 3 success sets up showdown with Roche, Sandoz, and Celltrion
Breast cancer blockbuster facing potential trio of US competitors.